| Oct 17 |
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
|
| Oct 17 |
Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab
|
| Oct 17 |
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
|
| Oct 9 |
Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV
|
| Oct 9 |
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
|
| Sep 26 |
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
|
| Sep 19 |
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays
|
| Sep 17 |
Theratechnologies Sees Risk of Supply Disruption for Its EGRIFTA SV Drug in Early 2025
|
| Sep 17 |
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
|
| Aug 26 |
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
|
